Form 4: Corcept Therapeutics CFO Sells Shares
Insider Transaction (Form 4)
Atabak Mokari, Chief Financial Officer of Corcept Therapeutics Inc, sold 80,000 shares of common stock on July 30, 2026.
Summary
- Option exercise/conversion: acquired 80,000 Common Stock at $23.06 ($1,844,800) on July 30, 2026; holds 96,130 after (Direct).
- Open-market sale: disposed of 4,200 Common Stock at $105.54 ($443,248) on July 30, 2026; holds 91,930 after (Direct).
- Open-market sale: disposed of 8,956 Common Stock at $106.96 ($957,892) on July 30, 2026; holds 82,974 after (Direct).
- Open-market sale: disposed of 400 Common Stock at $108.46 ($43,384) on July 30, 2026; holds 82,574 after (Direct).
- Open-market sale: disposed of 2,202 Common Stock at $110.03 ($242,282) on July 30, 2026; holds 80,372 after (Direct).
- Open-market sale: disposed of 600 Common Stock at $110.95 ($66,570) on July 30, 2026; holds 79,772 after (Direct).
- Open-market sale: disposed of 4,700 Common Stock at $113.18 ($531,941) on July 30, 2026; holds 75,072 after (Direct).
- Open-market sale: disposed of 15,477 Common Stock at $114.96 ($1,779,237) on July 30, 2026; holds 59,595 after (Direct).
- Open-market sale: disposed of 14,222 Common Stock at $115.87 ($1,647,859) on July 30, 2026; holds 45,373 after (Direct).
- Open-market sale: disposed of 7,089 Common Stock at $116.96 ($829,102) on July 30, 2026; holds 38,284 after (Direct).
- Open-market sale: disposed of 8,267 Common Stock at $117.93 ($974,951) on July 30, 2026; holds 30,017 after (Direct).
- Open-market sale: disposed of 4,783 Common Stock at $118.73 ($567,908) on July 30, 2026; holds 25,234 after (Direct).
- Open-market sale: disposed of 8,103 Common Stock at $119.95 ($971,939) on July 30, 2026; holds 17,131 after (Direct).
- Open-market sale: disposed of 1,001 Common Stock at $120.67 ($120,796) on July 30, 2026; holds 16,130 after (Direct).
- Option exercise/conversion: disposed of 80,000 Stock option (right to buy) on July 30, 2026; holds 95,833 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $9,177,109 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Atabak Mokari — Officer (Chief Financial Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-30 | Option exercise/conversion | Common Stock | 80,000 | $23 | $1.8M | 96,130 |
| 2026-07-30 | Open-market sale | Common Stock | 4,200 | $106 | $443.2K | 91,930 |
| 2026-07-30 | Open-market sale | Common Stock | 8,956 | $107 | $957.9K | 82,974 |
| 2026-07-30 | Open-market sale | Common Stock | 400 | $108 | $43.4K | 82,574 |
| 2026-07-30 | Open-market sale | Common Stock | 2,202 | $110 | $242.3K | 80,372 |
| 2026-07-30 | Open-market sale | Common Stock | 600 | $111 | $66.6K | 79,772 |
| 2026-07-30 | Open-market sale | Common Stock | 4,700 | $113 | $531.9K | 75,072 |
| 2026-07-30 | Open-market sale | Common Stock | 15,477 | $115 | $1.8M | 59,595 |
| 2026-07-30 | Open-market sale | Common Stock | 14,222 | $116 | $1.6M | 45,373 |
| 2026-07-30 | Open-market sale | Common Stock | 7,089 | $117 | $829.1K | 38,284 |
| 2026-07-30 | Open-market sale | Common Stock | 8,267 | $118 | $975.0K | 30,017 |
| 2026-07-30 | Open-market sale | Common Stock | 4,783 | $119 | $567.9K | 25,234 |
| 2026-07-30 | Open-market sale | Common Stock | 8,103 | $120 | $971.9K | 17,131 |
| 2026-07-30 | Open-market sale | Common Stock | 1,001 | $121 | $120.8K | 16,130 |
| 2026-07-30 | Option exercise/conversion | Stock option (right to buy) | 80,000 | — | — | 95,833 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-30 | Option exercise/conversion (80,000 shares) |
| 2026-07-30 | Open-market sale (4,200 shares) |
| 2026-07-30 | Open-market sale (8,956 shares) |
| 2026-07-30 | Open-market sale (400 shares) |
| 2026-07-30 | Open-market sale (2,202 shares) |
| 2026-07-30 | Open-market sale (600 shares) |
| 2026-07-30 | Open-market sale (4,700 shares) |
| 2026-07-30 | Open-market sale (15,477 shares) |
| 2026-07-30 | Open-market sale (14,222 shares) |
| 2026-07-30 | Open-market sale (7,089 shares) |
| 2026-07-30 | Open-market sale (8,267 shares) |
| 2026-07-30 | Open-market sale (4,783 shares) |
| 2026-07-30 | Open-market sale (8,103 shares) |
| 2026-07-30 | Open-market sale (1,001 shares) |
| 2026-07-30 | Option exercise/conversion (80,000 shares) |
Keywords
insider transaction, Form 4, CORT, CORCEPT THERAPEUTICS INC, bearish, Atabak Mokari
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.